Inhibition of CHIT1 as a novel therapeutic approach in idiopathic pulmonary fibrosis.

导出 LinkOut

翻译打印收藏纠错

作者： Piotr,Sklepkiewicz ^[1] ; Barbara A,Dymek ^[2] ; Michal,Mlacki ^[1] ; Robert,Koralewski ^[1] ; Marzena,Mazur ^[1] ; Patrycja,Nejman-Gryz ^[3] ; Serdar,Korur ^[1] ; Agnieszka,Zagozdzon ^[1] ; Aleksandra,Rymaszewska ^[1] ; Jan H,von der Thüsen ^[4] ; Anna M,Siwińska ^[1] ; Nazan Cemre,Güner ^[1] ; Łukasz,Cheda ^[1] ; Magdalena,Paplinska-Goryca ^[3] ; Małgorzata,Proboszcz ^[3] ; Thierry P P,van den Bosch ^[4] ; Katarzyna,Górska ^[3] ; Jakub,Golab ^[5] ; Rafał M,Kamiński ^[1] ; Rafał,Krenke ^[3] ; Adam,Golebiowski ^[1] ; Karolina,Dzwonek ^[1] ; Pawel,Dobrzanski ^[1]

作者单位： OncoArendi Therapeutics SA, 02-089, Warsaw, Poland. ^[1] OncoArendi Therapeutics SA, 02-089, Warsaw, Poland; Postgraduate School of Molecular Medicine, Medical University of Warsaw, 02-097, Warsaw, Poland. Electronic address: b.dymek@oncoarendi.com. ^[2] Department of Internal Medicine, Pulmonary Diseases and Allergy, Medical University of Warsaw, 02-097, Warsaw, Poland. ^[3] Department of Pathology, Erasmus Medical Center, 3015 GD, Rotterdam, the Netherlands. ^[4] Department of Immunology, Medical University of Warsaw, 02-097, Warsaw, Poland. ^[5]

关键词 Anti-fibrotics CHIT1 IPF OATD-01 OATD-01 (PubChem ID 126642132)Pirfenidone (PubChem ID 40632)Pulmonary fibrosis